Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant

CHEMBL4594584 Phase 4 已批准 Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
508.6 g/mol
LogP
-3.6
Phase
4

A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

分子量

508.6000 g/mol

LogP

-3.60

TPSA

197.00 Ų

Lipinski 五规则

不符合

作用机制

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCCC[C@@H](C(=O)O)N

InChI

InChI=1S/C21H40N4O10/c1-31-12-9-24-20(29)34-14-16(15-35-21(30)25-10-13-32-2)33-11-5-7-18(26)23-8-4-3-6-17(22)19(27)28/h16-17H,3-15,22H2,1-2H3,(H,23,26)(H,24,29)(H,25,30)(H,27,28)/t17-/m0/s1

Molecular Formula

C21H40N4O10

HBD / HBA

5 / 11

可旋转键数

23

重原子数

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594584. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86278357. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.